Treatment
| Surgery | HG-ESS and UUS Yes: 38; No: 1* |
| Path first (n (%)) | |
| Laparotomy | 32 (84.2) |
| Laparoscopy | 5 (13.2) |
| UK | 1 (2.6) |
| Type of surgery (n (%)) | |
| Total hysterectomy | 38 (100) |
| Bilateral oophorectomy | 26 (68.4) |
| Pelvic lymphadenectomy | 9 (23.7) |
| Pre-aortic lymphadenectomy | 3 (7.9) |
| Other | 5 (13.2) |
| Surgical resection | |
| Complete (TH+BO†) | 26 (68.4) |
| Incomplete | 9 (23.7) |
| UK | 3 (7.9) |
| Quality of resection‡ (n (%)) | |
| R0 | 23 (60.5) |
| R1 | 6 (15.8) |
| R2 | 2 (5.3) |
| UK | 7 (18.4) |
| Tumor rupture (n (%)) | |
| Yes | 6 (15.8) |
| No | 30 (78.9) |
| UK | 2 (5.3) |
| Adjuvant treatment | HG-ESS and UUS operated(n=38) |
| Adjuvant treatment (n (%)) | |
| Yes | 32 (84.2) |
| No | 6 (15.8) |
| Radiotherapy (n (%)) | |
| Yes | 22 (57.9) |
| No | 14 (36.8) |
| UK | 2 (5.3) |
| Brachytherapy (n (%)) | |
| Yes | 11 (28.9) |
| No | 24 (63.2) |
| UK | 3 (7.9) |
| Chemotherapy (n (%)) | |
| Yes (including 5 patients who had radiotherapy and chemotherapy) | 11 (28.9) |
| No | 24 (63.2) |
| UK | 3 (7.9) |
*Chemotherapy neoadjuvant, then best supportive care for 1 patient.
†TH+BO, total hysterectomy and bilateral oophorectomy.
‡Resection, histological analysis: R0, complete; R1, microscopically incomplete; R2, macroscopically incomplete.
HG-ESS, high grade endometrial stromal sarcoma; UK, unknown; UUS, undifferentiated uterine sarcoma .